SV2017005367A - Composiciones y métodos de uso para tratar trastornos metabólicos - Google Patents
Composiciones y métodos de uso para tratar trastornos metabólicosInfo
- Publication number
- SV2017005367A SV2017005367A SV2017005367A SV2017005367A SV2017005367A SV 2017005367 A SV2017005367 A SV 2017005367A SV 2017005367 A SV2017005367 A SV 2017005367A SV 2017005367 A SV2017005367 A SV 2017005367A SV 2017005367 A SV2017005367 A SV 2017005367A
- Authority
- SV
- El Salvador
- Prior art keywords
- methods
- compositions
- metabolic disorders
- treat metabolic
- treat
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Abstract
SE PROPORCIONAN MÉTODOS PARA TRATAR INDIVIDUOS CON UN TRASTORNO DEL METABOLISMO DE LA GLUCOSA Y/O UN TRASTORNO DEL PESO CORPORAL, Y COMPOSICIONES ASOCIADAS CON ESTOS
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462031063P | 2014-07-30 | 2014-07-30 | |
US201562195908P | 2015-07-23 | 2015-07-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2017005367A true SV2017005367A (es) | 2017-09-26 |
Family
ID=55179329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2017005367A SV2017005367A (es) | 2014-07-30 | 2017-01-25 | Composiciones y métodos de uso para tratar trastornos metabólicos |
Country Status (29)
Country | Link |
---|---|
US (3) | US9834586B2 (es) |
EP (1) | EP3174894B1 (es) |
JP (1) | JP6704358B2 (es) |
KR (1) | KR20170065026A (es) |
CN (1) | CN106573966B (es) |
AP (1) | AP2016009663A0 (es) |
AU (1) | AU2015296640B2 (es) |
BR (1) | BR112017001789A2 (es) |
CA (1) | CA2953827A1 (es) |
CL (1) | CL2017000201A1 (es) |
CO (1) | CO2017000614A2 (es) |
CR (1) | CR20170027A (es) |
DO (1) | DOP2017000025A (es) |
EA (1) | EA035581B1 (es) |
EC (1) | ECSP17005276A (es) |
ES (1) | ES2883158T3 (es) |
IL (1) | IL249793B (es) |
MD (1) | MD20170020A2 (es) |
MX (1) | MX370115B (es) |
MY (1) | MY192917A (es) |
PE (1) | PE20170771A1 (es) |
PH (1) | PH12017500153A1 (es) |
SG (2) | SG10201802098UA (es) |
SV (1) | SV2017005367A (es) |
TN (1) | TN2016000578A1 (es) |
TW (1) | TWI710570B (es) |
UA (1) | UA123432C2 (es) |
WO (1) | WO2016018931A1 (es) |
ZA (1) | ZA201700311B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子15(gdf−15)ポリペプチド |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
EP3099304A4 (en) | 2014-01-31 | 2018-01-10 | Mayo Foundation for Medical Education and Research | Novel therapeutics for the treatment of glaucoma |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AP2017009828A0 (en) | 2014-10-31 | 2017-03-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
TWI815793B (zh) | 2016-03-31 | 2023-09-21 | 美商恩格姆生物製藥公司 | 結合蛋白質及其使用方法 |
US10336812B2 (en) | 2016-05-10 | 2019-07-02 | Janssen Biotech, Inc. | GDF15 fusion proteins and uses thereof |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
MA50141A (fr) * | 2017-04-20 | 2020-07-29 | Novo Nordisk As | Procédés de purification de protéines de fusion d'albumine |
JP2020533302A (ja) | 2017-09-10 | 2020-11-19 | ノヴォ ノルディスク アー/エス | 肥満の治療において使用するためのmic−1およびglp−1 |
US11267863B2 (en) | 2018-01-19 | 2022-03-08 | Pepgene Inc. | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
TWI724392B (zh) | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
CA3096097A1 (en) | 2018-04-09 | 2019-10-17 | Amgen Inc. | Growth differentiation factor 15 fusion proteins |
CN112543869A (zh) | 2018-08-10 | 2021-03-23 | 诺华股份有限公司 | Gfral细胞外结构域和使用方法 |
US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
EP4041281A1 (en) | 2019-10-04 | 2022-08-17 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
KR20210065057A (ko) * | 2019-11-26 | 2021-06-03 | 주식회사유한양행 | 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물 |
US20230133672A1 (en) * | 2019-12-11 | 2023-05-04 | Lg Chem, Ltd. | Fusion polypeptide comprising gdf15 and polypeptide region capable of o-glycosylation |
EP4072543A4 (en) * | 2019-12-12 | 2024-02-07 | Qlaris Bio Inc | CONTROLLED RELEASE CROMAKALIM PRODRUGS |
CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5194596A (en) * | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US6180602B1 (en) | 1992-08-04 | 2001-01-30 | Sagami Chemical Research Center | Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent |
WO1994003599A1 (en) | 1992-08-04 | 1994-02-17 | Sagami Chemical Research Center | HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR |
JPH07250688A (ja) | 1994-01-28 | 1995-10-03 | Sagami Chem Res Center | TGF−βスーパーファミリー蛋白質をコードするヒト新規cDNA |
JPH07258293A (ja) | 1994-03-23 | 1995-10-09 | Asahi Chem Ind Co Ltd | 新規な蛋白質ならびにその製造方法 |
US6521227B1 (en) | 1999-11-18 | 2003-02-18 | Peter L. Hudson | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
WO1996018730A1 (en) | 1994-12-15 | 1996-06-20 | Human Genome Sciences, Inc. | Prostatic growth factor |
US5994102A (en) | 1994-12-15 | 1999-11-30 | Human Genome Sciences, Inc. | Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE69637844D1 (de) | 1995-06-22 | 2009-04-09 | St Vincent S Hospital Sidney L | Neues tgf-beta-ahnliches cytokin |
US6524802B1 (en) | 1996-03-29 | 2003-02-25 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-14 |
US6107476A (en) | 1996-09-11 | 2000-08-22 | Ortho-Mcneil Pharmaceutical, Inc. | Nucleic acid molecule encoding a protein growth factor for inhibiting prostate cancer cell growth |
AU8591198A (en) | 1997-07-31 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-15 |
WO2000005259A1 (en) | 1998-07-23 | 2000-02-03 | Smithkline Beecham Corporation | Secreted cysteine rich protein-6 (scrp-6) |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6465181B2 (en) | 1999-03-25 | 2002-10-15 | Abbott Laboratories | Reagents and methods useful for detecting diseases of the prostate |
US6974684B2 (en) | 2001-08-08 | 2005-12-13 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
CA2372119A1 (en) | 1999-05-17 | 2000-11-23 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrie B Von Pharmaka Mbh | Neuroprotective properties of gdf-15, a novel member of the tgf-.beta. superfamily |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
BRPI0109494B8 (pt) * | 2000-03-22 | 2021-05-25 | Octagene Gmbh | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii |
CA2405912A1 (en) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001081928A1 (en) | 2000-04-20 | 2001-11-01 | St Vincent's Hospital Sydney Limited | Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1) |
WO2002020759A2 (en) | 2000-09-08 | 2002-03-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties |
EP1354042A2 (en) | 2000-12-29 | 2003-10-22 | Curagen Corporation | Proteins and nucleic acids encoding same |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
AU2002250293B2 (en) | 2001-03-09 | 2007-10-11 | Arnason, Barry G. Mr | Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors |
EE05294B1 (et) | 2001-05-11 | 2010-04-15 | Amgen Inc. | TALL-1-ga seostuv ainekompositsioon |
GB0115195D0 (en) | 2001-06-21 | 2001-08-15 | Bae Systems Plc | Split-pin drill jig |
FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
US20030053431A1 (en) | 2001-09-10 | 2003-03-20 | Lila Madour | Method for performing handoff in a radio telecommunications network |
US20060253913A1 (en) | 2001-12-21 | 2006-11-09 | Yue-Jin Huang | Production of hSA-linked butyrylcholinesterases in transgenic mammals |
ES2545090T3 (es) | 2001-12-21 | 2015-09-08 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina y GCSF |
US7157235B2 (en) | 2002-06-17 | 2007-01-02 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
US7919084B2 (en) | 2002-06-17 | 2011-04-05 | St. Vincent's Hospital Sydney Limited | Methods of diagnosis, prognosis and treatment of cardiovascular disease |
CN1241946C (zh) | 2002-07-01 | 2006-02-15 | 美国福源集团 | 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白 |
EP1575512A4 (en) | 2002-11-08 | 2007-08-29 | Barnes Jewish Hospital | METHOD AND COMPOSITIONS FOR THE EPITHELIAL CELL DIFFERENTIATION IN THE PROSTATE |
US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
EP2774620A1 (en) | 2004-04-13 | 2014-09-10 | St Vincent's Hospital Sydney Limited | Method for modulating weight loss |
WO2005113585A2 (en) | 2004-05-20 | 2005-12-01 | Acceleron Pharma Inc. | Modified tgf-beta superfamily polypeptides |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
KR20070084069A (ko) | 2004-10-08 | 2007-08-24 | 도만티스 리미티드 | Tnfr1에 대한 단일 도메인 항체 및 이의 사용 방법 |
NZ560504A (en) | 2005-01-24 | 2009-07-31 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptidomimetics |
JP2007258293A (ja) | 2006-03-22 | 2007-10-04 | Fuji Electric Holdings Co Ltd | はんだ濡れ性評価装置およびはんだ濡れ性評価方法 |
TWI428448B (zh) | 2006-03-24 | 2014-03-01 | Syntonix Pharmaceuticals Inc | 作為第九因子(factor ix)原肽處理酶之pc5 |
US8974748B2 (en) | 2007-04-05 | 2015-03-10 | Corning Incorporated | Dual inlet microchannel device and method for using same |
US7754689B2 (en) | 2006-06-02 | 2010-07-13 | Wyeth Llc | Finger-1 peptide analogs of the TGF-β superfamily |
AU2007254824A1 (en) | 2006-06-02 | 2007-12-13 | Wyeth | Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods |
EP2052253A2 (en) | 2006-07-26 | 2009-04-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
BRPI0715126B8 (pt) | 2006-08-04 | 2021-07-27 | Medizinische Hochschule Hannover | métodos para avaliação do risco de intervenções cardíacas e usos à base de gdf-15 |
US8278096B2 (en) | 2007-04-25 | 2012-10-02 | Stem Cells Spin Spolka Akcyjna | Stem cell lines from deer antlers, their application and culture methods |
US8067548B2 (en) | 2007-07-26 | 2011-11-29 | Novagen Holding Corporation | Fusion proteins having mutated immunoglobulin hinge region |
CN101765608B (zh) | 2007-07-31 | 2015-03-11 | 阿菲博迪公司 | 新白蛋白结合组合物、方法及应用 |
US20100278843A1 (en) | 2007-08-16 | 2010-11-04 | St. Vincent's Hospital Sydney Limited | Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity |
JP2011502106A (ja) | 2007-10-09 | 2011-01-20 | セントビンセンツ ホスピタル シドニー リミテッド | マクロファージ阻害性サイトカイン−1を除去又は不活性化して悪液質を治療する方法 |
CA2701945A1 (en) | 2007-10-22 | 2009-04-30 | Samuel Norbert Breit | Methods of prognosis of overall survival using mic-1 |
RU2010121862A (ru) * | 2007-10-29 | 2011-12-10 | Вирджиния Тек Интеллекчуал Пропертиз, Инк. (Us) | DC-SIGN, ICAM-3 И LSECtin СВИНЬИ И ИХ ПРИМЕНЕНИЯ |
SI2235064T1 (sl) | 2008-01-07 | 2016-04-29 | Amgen Inc. | Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov |
WO2009087190A1 (en) | 2008-01-08 | 2009-07-16 | Roche Diagnostics Gmbh | Means and methods for assessing the risk of patients presenting to emergency units based on gdf-15 |
JP5647899B2 (ja) | 2008-01-08 | 2015-01-07 | ラツィオファルム ゲーエムベーハーratiopharm GmbH | オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化 |
EA018471B1 (ru) * | 2008-03-31 | 2013-08-30 | Глаксо Груп Лимитед | Слитые конструкции и конъюгаты лекарственного средства |
JP2011523051A (ja) | 2008-05-20 | 2011-08-04 | エフ.ホフマン−ラ ロシュ アーゲー | 1型糖尿病におけるバイオマーカーとしてのgdf−15 |
EP2318844A1 (en) | 2008-07-14 | 2011-05-11 | Roche Diagnostics GmbH | Multimarker panel for diagnosing, monitoring and selecting the therapy for patients with heart failure |
WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
MX349178B (es) | 2008-10-31 | 2017-07-17 | Centocor Ortho Biotech Inc | Diferenciación de células madre embrionarias humanas al linaje endocrino pancreático. |
WO2010048670A1 (en) | 2008-10-31 | 2010-05-06 | St Vincent's Hospital Sydney Limited | Method of prognosis in chronic kidney disease |
EP2211182A1 (en) | 2009-01-16 | 2010-07-28 | Roche Diagnostics GmbH | Method for the assessment of severity of liver cirrhosis |
EP2209003A1 (en) | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
CA2752157A1 (en) | 2009-02-12 | 2010-08-19 | Stryker Corporation | Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease |
GB0902737D0 (en) | 2009-02-19 | 2009-04-01 | Univ Gent | GDF15 as a differential marker for spondyloarthropathy |
CA2752647A1 (en) | 2009-02-24 | 2010-09-02 | The Salk Institute For Biological Studies | Designer ligands of tgf-beta superfamily |
SI3248610T1 (sl) | 2009-05-05 | 2024-03-29 | Amgen Inc., | Mutanti fgf21 in njihove uporabe |
CA2766166A1 (en) | 2009-07-08 | 2011-01-13 | Amgen Inc. | Design of stable and aggregation free antibody fc molecules through ch3 domain interface engineering |
US20130323835A1 (en) | 2009-07-15 | 2013-12-05 | Zirus, Inc. | Mammalian Genes Involved in Infection |
US20120309697A1 (en) | 2009-10-28 | 2012-12-06 | Samuel Norbert Breit | Methods of diagnosing and prognosing colonic polyps |
RU2585488C2 (ru) | 2009-11-05 | 2016-05-27 | Дженентек, Инк. | Способы и композиция для секреции гетерологичных полипептидов |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
SI2506871T1 (sl) | 2009-11-30 | 2016-12-30 | Janssen Biotech, Inc. | Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami |
US9212221B2 (en) | 2010-03-03 | 2015-12-15 | Detroit R & D, Inc. | Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses |
JP5791335B2 (ja) | 2010-04-07 | 2015-10-07 | 花王株式会社 | オルガノポリシロキサン化合物の製造方法 |
US20130202564A1 (en) | 2010-04-09 | 2013-08-08 | University Of Southern California | Systems and Methods of Cell Activated, Controlled Release Delivery of Growth Factors for Tissue Repair and Regeneration |
EP2383571A1 (en) | 2010-05-02 | 2011-11-02 | Prof. Hess Medical Consulting GmbH | Growth differntioation factor 15 (GDF 15) for risk prediction of diabetic foot ulcer |
CN105044349B (zh) | 2010-08-26 | 2018-04-06 | 弗·哈夫曼-拉罗切有限公司 | 生物标志物在评估从动脉高血压向心力衰竭的早期转变中的用途 |
EP2439535A1 (en) | 2010-10-07 | 2012-04-11 | F. Hoffmann-La Roche AG | Diagnosis of diabetes related heart disease and GDF-15 and Troponin as predictors for the development of type 2 diabetes mellitus |
CA2826142A1 (en) * | 2011-02-03 | 2012-08-09 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
MX343729B (es) * | 2011-04-08 | 2016-11-18 | Amgen Inc | Factor de diferenciación de crecimiento 15 (gdf-15) y composiciones del mismo para usarse en el tratamiento o mejoramiento de trastornos metabólicos. |
PT2697257T (pt) | 2011-04-13 | 2016-12-28 | Bristol Myers Squibb Co | Proteínas de fusão fc compreendendo novos ligantes ou arranjos |
CN103827300A (zh) | 2011-06-30 | 2014-05-28 | 中外制药株式会社 | 异源二聚化多肽 |
CN107090038A (zh) | 2011-06-30 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 抗c‑met抗体配制剂 |
JP2015506373A (ja) | 2012-01-26 | 2015-03-02 | アムジエン・インコーポレーテツド | 成長分化因子15(gdf−15)ポリペプチド |
CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
ES2784223T3 (es) | 2012-06-20 | 2020-09-23 | Univ Virginia Patent Foundation | Composiciones y procedimientos para regular la homeostasis de glucosa y la acción de insulina |
WO2014000042A1 (en) | 2012-06-27 | 2014-01-03 | Prince Henry's Institute Of Medical Research | COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
KR20150038012A (ko) | 2012-08-08 | 2015-04-08 | 로슈 글리카트 아게 | 인터루킨-10 융합 단백질 및 그의 용도 |
AR094271A1 (es) | 2012-12-21 | 2015-07-22 | Aveo Pharmaceuticals Inc | Anticuerpos anti-gdf15 |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
KR101993714B1 (ko) | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
SG10201808523RA (en) | 2013-03-15 | 2018-11-29 | Genentech Inc | Il-22 polypeptides and il-22 fc fusion proteins and methods of use |
CN203123206U (zh) * | 2013-04-01 | 2013-08-14 | 宋艳丽 | 一种简易式一次性防污染无菌注射器 |
UA116665C2 (uk) | 2013-07-31 | 2018-04-25 | Емджен Інк. | Гібридний білок, що містить область фактора диференціації та росту 15 (gdf-15) |
KR20230141929A (ko) | 2013-07-31 | 2023-10-10 | 암젠 인크 | Fc-함유 폴리펩타이드의 안정화 |
WO2016018931A1 (en) | 2014-07-30 | 2016-02-04 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
AP2017009828A0 (en) | 2014-10-31 | 2017-03-31 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
EP3393494A1 (en) | 2015-12-22 | 2018-10-31 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
-
2015
- 2015-07-28 WO PCT/US2015/042510 patent/WO2016018931A1/en active Application Filing
- 2015-07-28 AP AP2016009663A patent/AP2016009663A0/en unknown
- 2015-07-28 EA EA201692477A patent/EA035581B1/ru unknown
- 2015-07-28 AU AU2015296640A patent/AU2015296640B2/en active Active
- 2015-07-28 ES ES15827485T patent/ES2883158T3/es active Active
- 2015-07-28 US US14/811,578 patent/US9834586B2/en active Active
- 2015-07-28 PE PE2017000103A patent/PE20170771A1/es unknown
- 2015-07-28 MX MX2017000964A patent/MX370115B/es active IP Right Grant
- 2015-07-28 CA CA2953827A patent/CA2953827A1/en active Pending
- 2015-07-28 UA UAA201700670A patent/UA123432C2/uk unknown
- 2015-07-28 MY MYPI2017700310A patent/MY192917A/en unknown
- 2015-07-28 CN CN201580041716.9A patent/CN106573966B/zh active Active
- 2015-07-28 KR KR1020177002592A patent/KR20170065026A/ko unknown
- 2015-07-28 TN TN2016000578A patent/TN2016000578A1/en unknown
- 2015-07-28 MD MDA20170020A patent/MD20170020A2/ro not_active Application Discontinuation
- 2015-07-28 BR BR112017001789-0A patent/BR112017001789A2/pt active Search and Examination
- 2015-07-28 EP EP15827485.2A patent/EP3174894B1/en active Active
- 2015-07-28 JP JP2016576027A patent/JP6704358B2/ja active Active
- 2015-07-28 SG SG10201802098UA patent/SG10201802098UA/en unknown
- 2015-07-28 SG SG11201700378PA patent/SG11201700378PA/en unknown
- 2015-07-28 TW TW104124401A patent/TWI710570B/zh active
- 2015-07-28 CR CR20170027A patent/CR20170027A/es unknown
-
2016
- 2016-12-27 IL IL249793A patent/IL249793B/en unknown
-
2017
- 2017-01-13 ZA ZA2017/00311A patent/ZA201700311B/en unknown
- 2017-01-24 PH PH12017500153A patent/PH12017500153A1/en unknown
- 2017-01-25 DO DO2017000025A patent/DOP2017000025A/es unknown
- 2017-01-25 EC ECIEPI20175276A patent/ECSP17005276A/es unknown
- 2017-01-25 SV SV2017005367A patent/SV2017005367A/es unknown
- 2017-01-25 CL CL2017000201A patent/CL2017000201A1/es unknown
- 2017-01-25 CO CONC2017/0000614A patent/CO2017000614A2/es unknown
- 2017-11-01 US US15/801,198 patent/US20180134761A1/en not_active Abandoned
-
2020
- 2020-02-07 US US16/784,877 patent/US11358995B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SV2017005367A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
GT201700072A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
TWD170335S (zh) | 錶 | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
TWD170341S (zh) | 手錶 | |
TWD170355S (zh) | 項鍊 | |
EA201692529A1 (ru) | Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов | |
EA201692109A1 (ru) | Варианты антител к фактору d и их применение | |
CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares | |
EA201692395A1 (ru) | Новые соединения | |
PH12016501658A1 (en) | Sialylated glycoprotein compositions and uses thereof | |
DOP2015000290A (es) | Benzoxazoles sustituidos | |
TWD177062S (zh) | 按摩器 | |
TWD169874S (zh) | 調棒 | |
TWD175566S (zh) | 雪鏡 | |
TWD169829S (zh) | 運動用棒 | |
TWD170787S (zh) | 項鍊 |